Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
51655-0933-04 51655-0933 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct 25, 2022 In Use
57894-0449-01 57894-0449 Teclistamab-cqyv TECVAYLI 10.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
59572-0775-01 59572-0775 Luspatercept Reblozyl 75.0 mg/1 Immunotherapy Erythropoiesis-Stimulating Agent Subcutaneous Nov 8, 2019 In Use
72266-0252-01 72266-0252 Cisplatin CISPLATIN 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug 11, 2023 In Use
68788-6976-01 68788-6976 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Jun 6, 2017 In Use
70377-0050-12 70377-0050 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Mar 3, 2025 In Use
71205-0729-10 71205-0729 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec 12, 2022 In Use
82868-0026-30 82868-0026 Estradiol Estradiol 2.0 mg/1 Hormonal Therapy Estrogen Oral Nov 9, 2023 In Use
13668-0682-60 13668-0682 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral Apr 12, 2023 In Use
63187-0709-20 63187-0709 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 1, 2016 In Use
00781-3258-70 00781-3258 bortezomib for injection Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous May 31, 2022 In Use
83703-0532-01 83703-0532 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
55513-0078-01 55513-0078 Talimogene Laherparepvec Imlygic 1000000.0 [PFU]/mL Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus Intralesional Nov 2, 2015 In Use
72205-0081-30 72205-0081 Erlotinib Hydrochloride Erlotinib Hydrochloride 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 11, 2021 In Use
57664-0020-97 57664-0020 Isotretinoin Isotretinoin 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec 29, 2020 In Use
16729-0276-67 16729-0276 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Mar 14, 2014 In Use
00069-1306-10 00069-1306 epoetin alfa-epbx RETACRIT 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Jun 18, 2018 In Use
00078-1161-47 00078-1161 Trametinib Mekinist 0.05 mg/mL Chemotherapy MEK Inhibitor BRAF Oral Mar 16, 2023 In Use
25021-0801-66 25021-0801 Zoledronic Acid Zoledronic Acid 0.8 mg/mL Ancillary Therapy Bisphosphonate Intravenous Dec 29, 2014 In Use
16714-0131-01 16714-0131 Irinotecan hydrochloride Irinotecan hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov 15, 2020 In Use
51013-0190-30 51013-0190 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral May 29, 2018 In Use
62332-0678-10 62332-0678 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb 28, 2023 In Use
55154-4567-00 55154-4567 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 2, 2007 In Use
63629-6709-02 63629-6709 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 28, 2015 In Use
84549-0781-05 84549-0781 Triamcinolone Acetonide Triamcinolone Acetonide 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-arterial, Intramuscular Sep 8, 2025 In Use

Found 12611 results — Export these results